Semaglutide
GLP-1 receptor agonist reference standard for metabolic research.
Semaglutide is an acylated GLP-1 receptor agonist analogue. Supplied as a research reference standard for in vitro metabolic pathway studies, receptor binding assays, and comparative pharmacology research. ≥99% purity, MS identity confirmed.
Semaglutide: Long-Acting GLP-1 Agonist
Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk (marketed as Ozempic and Wegovy). With a molecular weight of approximately 4,114 Da, semaglutide incorporates a fatty acid side chain—a structural modification that enables albumin binding and creates an extended half-life in circulation. This pharmacokinetic feature has made semaglutide the most extensively studied GLP-1 analog in the published literature, with hundreds of peer-reviewed studies examining its effects across metabolic disease models, glucose regulation paradigms, and weight reduction research in animals and humans alike.
The research foundation for semaglutide is exceptionally robust. Published work spans obesity models, type 2 diabetes phenotypes, cardiovascular outcome studies, and mechanistic investigations into GLP-1 signaling at the cellular level. The albumin-binding strategy has been the subject of pharmacokinetic research examining drug disposition, tissue distribution, and sustained receptor activation. Because of semaglutide's widespread use in research contexts, the scientific literature provides abundant context for experimental design, dosing ranges, and expected outcomes in common model systems. Our semaglutide research article aggregates key findings and citations for research planning.
Purity and identity verification for semaglutide should meet the same rigorous standards as other synthetic peptides. HPLC purity documentation (typically ≥99%) must be accompanied by mass spectrometry confirmation of the albumin-binding side chain and overall molecular structure. The fatty acid modification makes semaglutide slightly more sensitive to oxidation than unmodified peptides, so analytical methods should include peroxide testing. Request sterility and endotoxin assays, and verify batch traceability through your supplier's documentation system—especially important given semaglutide's high research demand.
Storage stability for semaglutide requires -20°C or colder prior to use; once reconstituted, maintain at 2-8°C and use within 2-4 weeks. The fatty acid side chain, while providing pharmacokinetic advantages, increases susceptibility to aggregation if stored improperly. Avoid vigorous shaking during reconstitution—gentle mixing preserves the peptide's structural integrity. For comparative research examining GLP-1 agonist mechanisms, consider tirzepatide (dual GLP-1/GIP agonist) or retatrutide (triple agonist).
Lone Star Peptide ships same-day to research institutions across all of Texas. Same-state logistics mean shorter cold-chain transit and faster delivery than any out-of-state supplier — with COA documentation that meets institutional procurement standards statewide.
Tested
Included
Houston
Semaglutide: Long-Acting GLP-1 Agonist
Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk (marketed as Ozempic and Wegovy). With a molecular weight of approximately 4,114 Da, semaglutide incorporates a fatty acid side chain—a structural modification that enables albumin binding and creates an extended half-life in circulation. This pharmacokinetic feature has made semaglutide the most extensively studied GLP-1 analog in the published literature, with hundreds of peer-reviewed studies examining its effects across metabolic disease models, glucose regulation paradigms, and weight reduction research in animals and humans alike.
The research foundation for semaglutide is exceptionally robust. Published work spans obesity models, type 2 diabetes phenotypes, cardiovascular outcome studies, and mechanistic investigations into GLP-1 signaling at the cellular level. The albumin-binding strategy has been the subject of pharmacokinetic research examining drug disposition, tissue distribution, and sustained receptor activation. Because of semaglutide's widespread use in research contexts, the scientific literature provides abundant context for experimental design, dosing ranges, and expected outcomes in common model systems. Our semaglutide research article aggregates key findings and citations for research planning.
Purity and identity verification for semaglutide should meet the same rigorous standards as other synthetic peptides. HPLC purity documentation (typically ≥99%) must be accompanied by mass spectrometry confirmation of the albumin-binding side chain and overall molecular structure. The fatty acid modification makes semaglutide slightly more sensitive to oxidation than unmodified peptides, so analytical methods should include peroxide testing. Request sterility and endotoxin assays, and verify batch traceability through your supplier's documentation system—especially important given semaglutide's high research demand.
Storage stability for semaglutide requires -20°C or colder prior to use; once reconstituted, maintain at 2-8°C and use within 2-4 weeks. The fatty acid side chain, while providing pharmacokinetic advantages, increases susceptibility to aggregation if stored improperly. Avoid vigorous shaking during reconstitution—gentle mixing preserves the peptide's structural integrity. For comparative research examining GLP-1 agonist mechanisms, consider tirzepatide (dual GLP-1/GIP agonist) or retatrutide (triple agonist).
FOR RESEARCH USE ONLY, Semaglutide is supplied exclusively for in vitro and laboratory research applications. Not approved by the FDA for human consumption or therapeutic use. Not a drug, supplement, or medical treatment. Purchasers are responsible for compliance with all applicable regulations.